Population PK Modeling and Simulation
FDA in its Critical Path Initiative is increasingly advocating the use of pharmaco-statistical models to support improved drug development decision-making. Pharsight scientists offer expertise in all aspects of sparse data analysis:
- PK/PD modeling of sparse and rich data
- Model discrimination and validation together with Monte Carlo simulation
- Sparse sampling strategies
- Population PK/PD analyses
- Special populations: pediatrics
- Parametric and nonparametric population PK/PD analyses